High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.11.020) (Early Online Publication)

Abstract

Background: Patients with heart failure with reduced ejection fraction (HFrEF) and sinus rhythm have a heightened risk of stroke. Whether anticoagulation benefits these patients is uncertain. In this post hoc analysis of the A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER-HF) trial we evaluated how a previously validated risk model consisting of 3 variables (history of prior stroke, insulin-treated diabetes, and N-terminal pro-B-type natriuretic peptide level) would perform, compared with plasma d-dimer, for stroke prediction and estimation of the benefit of low-dose rivaroxaban. Methods and Results: Stroke risk and treatment effect were computed across risk score and plasma d-dimer tertiles. Risk score was available in 58% of the COMMANDER-HF population (n = 2928). Over a median follow-up of 512 days (range 342–747 days), 60 patients experienced a stroke (14.6 per 1000 patient-years). The risk model did not identify patients at higher risk of stroke and showed a low overall prognostic performance (C-index = 0.53). The effect of rivaroxaban on stroke was homogeneous across risk score tertiles (P-interaction = .67). Among patients in whom the risk score was estimated, d-dimer was available in 2343 (80%). d-dimer had an acceptable discrimination performance for stroke prediction (C-index = 0.66) and higher plasma d-dimer concentrations were associated with higher rates of stroke (ie, tertile 3 vs tertile 1, hazard ratio 3.65, 95% confidence interval 1.59–8.39, P = .002). Treatment with low-dose rivaroxaban reduced the incidence of stroke in patients at highest risk by d-dimer levels (ie, >515 ng/mL, hazard ratio 0.42, 95% confidence interval 0.18–0.95, P-interaction = .074), without any safety concerns. Conclusions: In our analysis, plasma d-dimer concentrations performed better than a previously described 3-variable risk score for stroke prediction in patients with heart failure with reduced ejection fraction, a recent clinical worsening and sinus rhythm as enrolled in the COMMANDER-HF trial. In these patients, a raised plasma d-dimer concentration identified patients who might benefit most from rivaroxaban.

• Item Type: Articles
• Additional Information: The COMMANDER-HF trial was supported by Janssen Research and Development. T.K. receives grants from the Uehara Memorial Foundation and the Japanese Heart Failure Society Tsuchiya Foundation for research activity at the University of Glasgow.
• Keywords: Stroke, risk score, HFrEF, COMMANDER-HF, sinus rhythm, D-dimer.
• Status: Early Online Publication
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Kondo, Dr Toru and Cleland, Professor John and Ferreira, Mr Joao Pedro and McMurray, Professor John
• Authors: Monzo, L., Girerd, N., Ferreira, J. P., Lamiral, Z., Anker, S. D., Cleland, J. G. F., Kondo, T., McMurray, J. J. V., Lam, C. S. P., Mehra, M. R., van Veldhuisen, D. J., Greenberg, B., and Zannad, F.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Journal of Cardiac Failure
• Publisher: Elsevier
• ISSN: 1071-9164
• ISSN (Online): 1532-8414
• Published Online: 18 December 2023